178 related articles for article (PubMed ID: 38426070)
1. Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer.
Al Naji H; Winter JM; Pedersen SK; Roy A; Byrne SE; Young GP; Symonds EL
Biomark Insights; 2024; 19():11772719241232870. PubMed ID: 38426070
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection.
Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP
Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114
[TBL] [Abstract][Full Text] [Related]
3. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence.
Pedersen SK; Symonds EL; Roy AC; Cornthwaite KJ; LaPointe LC; Young GP
Cancer Med; 2023 Jan; 12(2):1319-1329. PubMed ID: 35822405
[TBL] [Abstract][Full Text] [Related]
4. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
5. Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.
Pedersen SK; Musher BL; LaPointe LC; Tuck MK; Symonds EL; Loayza N; Young GP
Cancer; 2022 May; 128(10):1921-1928. PubMed ID: 35290664
[TBL] [Abstract][Full Text] [Related]
6. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.
Symonds EL; Pedersen SK; Yeo B; Al Naji H; Byrne SE; Roy A; Young GP
Mol Oncol; 2022 May; 16(10):2031-2041. PubMed ID: 35000264
[TBL] [Abstract][Full Text] [Related]
7. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.
Young GP; Pedersen SK; Mansfield S; Murray DH; Baker RT; Rabbitt P; Byrne S; Bambacas L; Hollington P; Symonds EL
Cancer Med; 2016 Oct; 5(10):2763-2772. PubMed ID: 27726312
[TBL] [Abstract][Full Text] [Related]
9.
Laven-Law G; Kichenadasse G; Young GP; Symonds EL; Winter JM
Biomarkers; 2024 Jun; 29(4):194-204. PubMed ID: 38644767
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer.
Young GP; Symonds EL; Nielsen HJ; Ferm L; Christensen IJ; Dekker E; van der Vlugt M; Mallant-Hent RC; Boulter N; Yu B; Chan M; Tevz G; LaPointe LC; Pedersen SK
Clin Epigenetics; 2021 Jan; 13(1):14. PubMed ID: 33478584
[TBL] [Abstract][Full Text] [Related]
11. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Circulating Tumor DNA for Methylated
Musher BL; Melson JE; Amato G; Chan D; Hill M; Khan I; Kochuparambil ST; Lyons SE; Orsini J; Pedersen SK; Robb B; Saltzman J; Silinsky J; Gaur S; Tuck MK; LaPointe LC; Young GP
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2702-2709. PubMed ID: 32958500
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia.
Pedersen SK; Symonds EL; Baker RT; Murray DH; McEvoy A; Van Doorn SC; Mundt MW; Cole SR; Gopalsamy G; Mangira D; LaPointe LC; Dekker E; Young GP
BMC Cancer; 2015 Oct; 15():654. PubMed ID: 26445409
[TBL] [Abstract][Full Text] [Related]
15. Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and tissues of colorectal, breast and prostate cancer patients.
Winter JM; Sheehan-Hennessy L; Yao B; Pedersen SK; Wassie MM; Eaton M; Chong M; Young GP; Symonds EL
Cancer Biomark; 2022; 34(3):493-503. PubMed ID: 35253733
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
17. Variables Associated with Detection of Methylated
Saluja H; Young GP; Kholmurodova F; Symonds EL
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):774-781. PubMed ID: 33500319
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
19. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
